|
|
Inpatient and Outpatient Orderable
Acylcarnitine Profile, Quantitative, Plasma
Synonyms
|
- ACYL CARNITINE, PLASMA
- ACYLCARNITINES, PLASMA, QUANTITATIVE
- LAB429
|
Cerner Name
|
Acylcarnitine, Quant Plasma
|
Clinical Info
|
Used in the diagnosis and monitoring of inherited disorders of fatty acid oxidation and organic acidurias. May be used as a follow-up test to some abnormal newborn screen results.
|
Specimen Sources
|
Blood, Arterial
Blood, Capillary
Blood, Central Line
Blood, Venous
|
Specimen Types
|
Blood
|
Specimen Volume
|
1 mL plasma (minimum volume: 0.1 mL)
|
Container
|
Green Top Tube
|
Collection Instructions
|
Container/Tube: Green-top (sodium heparin) Specimen: 1 mL plasma (minimum volume: 0.1 mL)
Transport Temperature: Frozen
Stability: 2 - 8 Weeks Frozen
Note: Centrifuge immediately after collection and pour off plasma in transport vial. Freeze immediately.
|
Transport Instructions
|
Frozen
|
Specimen Stability
|
2 - 8 Weeks Frozen
Note: Centrifuge immediately after collection and pour off plasma in transport vial. Freeze immediately.
|
Methodology
|
Flow injection/tandem mass spectrometry
|
Days Performed
|
TAT: 4-8 Days
|
Performing Laboratory
|
LabCorp
|
CPT
|
82017
|
PDM
|
5910515
|
Only Orderable at Locations:
|
Orderable Everywhere
|
Results
|
| Component Name |
Base Name |
Common Name |
External Name |
| C2 |
C2 |
C2 |
C2 |
| ACYL C3 |
ACYLC3 |
ACYL C3 |
C3 |
| C3-DC |
C3DC |
C3 DC |
C3-Dicarboxylic |
| C4 |
C4 |
C4 |
C4 |
| C4-OH |
C4OH |
C4 OH |
C4-Hydroxy |
| C4-DC |
C4D |
C4 DC |
C4-Dicarboxylic |
| C5 |
C5 |
C5 |
C5 |
| C5:1 |
C5 |
C51 |
C5:1 |
| C5-OH |
C5 |
C5 OH |
C5-Hydroxy |
| C5-DC |
C5 |
C5 DC |
C5-Dicarboxylic |
| C6 |
C6 |
C6 |
C6 |
| C8 |
C8 |
C8 |
C8 |
| C10 |
C10 |
C10 |
C10 |
| C10:1 |
C10 |
C101 |
C10:1 |
| C10:2 |
C10 |
C102 |
C10:2 |
| C12 |
C12 |
C12 |
C12 |
| C14 |
C14 |
C14 |
C14 |
| C14:1 |
C141 |
C141 |
C14:1 |
| C14:2 |
C142 |
C142 |
C14:2 |
| C14-OH |
C14OH |
C14 OH |
C14-Hydroxy |
| C16 |
C16 |
C16 |
C16 |
| C16:1 |
C16 |
C161 |
C16:1 |
| C16:1-OH |
C16 |
C161 OH |
C16:1-Hydroxy |
| C16-OH |
C16 |
C16 OH |
C16-Hydroxy |
| C18 |
C18 |
C18 |
C18 |
| C18:1 |
C181 |
C181 |
C18:1 |
| C18:2 |
C182 |
C182 |
C18:2 |
| C18-OH |
C18OH |
C18 OH |
C18-Hydroxy |
| C18:1-OH |
C181OH |
C181 OH |
C18:1-Hydroxy |
| C18:2-OH |
C182OH |
C182 OH |
C18:2-Hydroxy |
| INTERPRETATION ACP |
ACPINT |
INTERPRETATION ACP |
ACP Interpretation |
| DIRECTOR REVIEW ACP |
DIRREVIEW |
DIRECTOR REVIEW ACP |
ACP Director Review |
| METHODOLOGY ACP |
METHODOLOGY |
METHODOLOGY, ACP |
ACP Methodology |
| DISCLAIMER |
DISCLAIM |
DISCLAIMER |
Disclaimer |
|
Result Interpretation
See report. TAT 4 - 7 Days
Units: umol/L
Includes:
C2 ,C3, C3-Dicarboylic, C4, C4-Hydroxy, C4-Dicarboxylic, C5, C5:1, c5-Hydroxy, C5-Dicarboxylic, C6, C8, C10, C10:1, C10:2, C12, C14, C14:1, C14:2 ,C14-Hydroxy, C16, C16:1, C16:1-Hydroxy, C16-Hydroxy, C18, C18:1, C18:2, C18-Hydroxy, C18:1-Hydroxy, C18:2-Hydroxy
Limitations
False-negative results can occur with acylcarnitine profiling, especially when the patient is carnitine deficient, is affected with a milder variant of a disorder, or when clinical condition or dietary supplementation causes secondary changes to the profile. Results of acylcarnitine profiling should be interpreted in the context of clinical presentation as well as other laboratory tests, which may include urine organic acid analysis and molecular testing.
This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA).
|
Forms
|
|
LAB429
|
